Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model.

In designing clinical trials of novel TB regimens, investigators should consider that even small changes in treatment efficacy may have considerable impact on TB-related incidence and mortality. Other regimen improvements may still have important benefits for resource allocation and outcomes such as patient quality of life.